PMID- 33533909
OWN - NLM
STAT- MEDLINE
DCOM- 20220427
LR  - 20220427
IS  - 1460-2385 (Electronic)
IS  - 0931-0509 (Linking)
VI  - 37
IP  - 4
DP  - 2022 Mar 25
TI  - Anti-myeloperoxidase and proteinase 3 antibodies for nephritis flare prediction 
      in anti-neutrophil cytoplasmic antibody-associated vasculitis.
PG  - 697-704
LID - 10.1093/ndt/gfab020 [doi]
AB  - BACKGROUND: The value of myeloperoxidase (MPO) and proteinase 3 (PR3) antibody 
      titres in the assessment of renal disease activity and flare prediction in 
      patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is 
      not well known. METHODS: We performed a retrospective study including 113 AVV 
      patients with renal biopsy-proven pauci-immune necrotizing glomerulonephritis 
      from seven Spanish hospitals. The main inclusion criteria were assessment of MPO 
      antibodies using multiplex flow immunoassay and PR3 antibody measurements using 
      immunoassay chemiluminescence with an identical range of values for all 
      participating centres. RESULTS: Serum MPO antibodies 3 +/- 1.2 months before 
      relapse were higher in patients who relapsed [19.2 +/- 12.2 versus 3.2 +/- 5.1 
      antibody index (AI); P < 0.001]. The discrimination value of MPO antibodies 
      3 months before renal relapse had an area under the receiver operating 
      characteristics curve (AUC) of 0.82 [95% confidence interval (CI) 0.73-0.92; 
      P < 0.001]. DeltaMPO antibodies (change in antibodies titration 6 months before 
      relapse) were higher in patients who relapsed (8.3 +/- 12 versus 0.9 +/- 3.1 AI; 
      P = 0.001). The discrimination value of DeltaMPO had an AUC of 0.76 (95% CI 
      0.63-0.88; P < 0.001). The positive predictive value of renal relapse in PR3 
      patients is 100% and the negative predictive value of renal relapse in patients 
      with PR3-positive titres is 57.1%. Serum PR3 antibodies were higher in patients 
      who relapsed 2.8 +/- 1.4 months before relapse (58.6 +/- 24.6 versus 2.0 +/- 0.6 AI; 
      P < 0.001). CONCLUSIONS: MPO level monitoring using multiplex flow immunoassay 
      and PR3 measurements using immunoassay chemiluminescence are useful and sensitive 
      tools for the prediction of renal relapse in the follow-up of AAV patients with 
      renal disease and relevant surrogate markers of renal disease activity.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.
FAU - Rodriguez, Eva
AU  - Rodriguez E
AD  - Servicio de Nefrologia, Hospital del Mar, Barcelona, Spain.
FAU - Latzke, Belen
AU  - Latzke B
AD  - Servicio de Nefrologia, Hospital del Mar, Barcelona, Spain.
FAU - Sierra, Milagros
AU  - Sierra M
AD  - Servicio de Nefrologia, Hospital San Pedro de Logrono, La Rioja, Spain.
FAU - Romera, Ana Maria
AU  - Romera AM
AD  - Servicio de Nefrologia, Hospital General Universitario de Ciudad Real, Ciudad 
      Real, Spain.
FAU - Siedel, Diego
AU  - Siedel D
AD  - Servicio de Nefrologia, Hospital General Universitario de Ciudad Real, Ciudad 
      Real, Spain.
FAU - Agraz, Irene
AU  - Agraz I
AD  - Servicio de Nefrologia, Hospital Universitario Valle Hebron, Barcelona, Spain.
FAU - Soler, Maria Jose
AU  - Soler MJ
AUID- ORCID: 0000-0003-3621-0766
AD  - Servicio de Nefrologia, Hospital Universitario Valle Hebron, Barcelona, Spain.
FAU - Garcia-Carro, Clara
AU  - Garcia-Carro C
AD  - Servicio de Nefrologia, Hospital Universitario Valle Hebron, Barcelona, Spain.
FAU - Draibe, Juliana
AU  - Draibe J
AD  - Hospital Universitario de Bellvitge, Barcelona, Spain.
FAU - de la Prada, Francisco Jose
AU  - de la Prada FJ
AD  - Servicio de Nefrologia, Hospital Universitario Virgen Macarena, Sevilla, Spain.
FAU - Villacorta, Javier
AU  - Villacorta J
AUID- ORCID: 0000-0001-8042-3545
AD  - Servicio Nefrologia, Hospital Universitario Ramon y Cajal, Madrid, Spain.
FAU - Buxeda, Anna
AU  - Buxeda A
AD  - Servicio de Nefrologia, Hospital del Mar, Barcelona, Spain.
FAU - Sierra-Ochoa, Adriana
AU  - Sierra-Ochoa A
AD  - Servicio de Nefrologia, Hospital del Mar, Barcelona, Spain.
FAU - Lozano, Ines
AU  - Lozano I
AD  - Laboratori de Referencia de Catalunya, Barcelona, Spain.
FAU - Duran, Xavier
AU  - Duran X
AD  - AMIB, Institut Hospital del Mar Investigacion Medica, Barcelona, Spain.
FAU - Barrios, Clara
AU  - Barrios C
AD  - Servicio de Nefrologia, Hospital del Mar, Barcelona, Spain.
FAU - Pascual, Julio
AU  - Pascual J
AD  - Servicio de Nefrologia, Hospital del Mar, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 3.4.21.76 (Myeloblastin)
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated 
      Vasculitis/complications/diagnosis
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - Female
MH  - Humans
MH  - *Kidney Diseases
MH  - Male
MH  - Myeloblastin
MH  - *Nephritis
MH  - Peroxidase
MH  - Recurrence
MH  - Retrospective Studies
OTO - NOTNLM
OT  - ANCA-associated vasculitides
OT  - myeloperoxidase antibodies
OT  - pauci-immune necrotizing glomerulonephritis flare
OT  - proteinase-3 antibodies
EDAT- 2021/02/04 06:00
MHDA- 2022/04/28 06:00
CRDT- 2021/02/03 12:13
PHST- 2020/03/10 00:00 [received]
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2022/04/28 06:00 [medline]
PHST- 2021/02/03 12:13 [entrez]
AID - 6127181 [pii]
AID - 10.1093/ndt/gfab020 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 2022 Mar 25;37(4):697-704. doi: 10.1093/ndt/gfab020.